Pharmaceutical - Respiratory and Pulmonary, Global

Filter

Popular Filters

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

Global asthma treatment market to reach $21.6 billion by 2019

09-10-2013

The global asthma treatment market is estimated to reach a value of $21.6 billion by 2019, due not only…

GlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Galapagos and AbbVie enter into cystic fibrosis alliance

Galapagos and AbbVie enter into cystic fibrosis alliance

24-09-2013

Belgium-based Galapagos and US drugmaker AbbVie have entered into a global alliance to discover novel…

GlobalPharmaceuticalResearchRespiratory and Pulmonary

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022

29-08-2013

The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

Global asthma market to reach 159 million lifetime cases by 2022

16-06-2013

Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion.…

GlaxoSmithKlineGlobalMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySeretideSingulair

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

Global asthma and COPD drug market to reach nearly $27 billion in 2017

19-06-2012

The global asthma and chronic obstructive pulmonary disease (COPD) market was worth $25.102 billion in…

GlobalMarkets & MarketingPharmaceuticalRespiratory and Pulmonary

Back to top